Kathleen K Schoemaker insider trades: Evoke Pharma (EVOK) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kathleen reports to the SEC
and 26 more companies
Open-market buys and sales
163 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 18, 2015 | EVOK | ↓ Sell | 11,836 | $7.02 | $83K | Direct | Aug 20, 2015 (2d) |
| Aug 18, 2015 | EVOK | ↓ Sell | 202 | $7.02 | $1K | Direct | Aug 20, 2015 (2d) |
| May 4, 2015 | TBRA | ↑ Buy | 277,777 | $10.62 | $2.9M | Direct | May 6, 2015 (2d) |
| Apr 16, 2015 | EVOK | ↓ Sell | 50,163 | $7.29 | $366K | Direct | Apr 16, 2015 (0d) |
| Apr 16, 2015 | EVOK | ↓ Sell | 857 | $7.29 | $6K | Direct | Apr 16, 2015 (0d) |
| Nov 25, 2014 | NEOT | ↑ Buy | 70,000 | $14.00 | $980K | Direct | Nov 26, 2014 (1d) |
| Oct 21, 2014 | ESPR | ↑ Buy | 500,000 | $20.00 | $10.0M | Direct | Oct 21, 2014 (0d) |
| Oct 21, 2014 | ATRA | ↑ Buy | 248,159 | $11.00 | $2.7M | Direct | Oct 21, 2014 (0d) |
| Oct 21, 2014 | ATRA | ↑ Buy | 1,841 | $11.00 | $20K | Direct | Oct 21, 2014 (0d) |
| Aug 5, 2014 | MRNS | ↑ Buy | 419,744 | $8.00 | $3.4M | Direct | Aug 7, 2014 (2d) |
| Jan 16, 2014 | ALIM | ↓ Sell | 296,760 | $6.39 | $1.9M | Direct | Jan 17, 2014 (1d) |
| Jan 16, 2014 | ALIM | ↓ Sell | 3,240 | $6.39 | $21K | Direct | Jan 17, 2014 (1d) |
| Aug 27, 2013 | RGDO | ↑ Buy | 750,000 | $4.00 | $3.0M | By Domain Partners VI, L.P. | Aug 28, 2013 (1d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 988,285 | $6.03 | $6.0M | By Domain Partners VIII, L.P. | Jul 16, 2013 (1d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 331,873 | $6.03 | $2.0M | By Domain Partners VI, L.P. | Jul 16, 2013 (1d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 7,333 | $6.03 | $44K | By DP VIII Associates, L.P. | Jul 16, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 280,923 | $14.00 | $3.9M | By Domain Partners VII, L.P. | Jul 2, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 4,791 | $14.00 | $67K | By DP VII Associates, L.P. | Jul 2, 2013 (1d) |
| Jun 20, 2013 | ALIM | ↓ Sell | 10,516 | $5.01 | $53K | Direct | Jun 24, 2013 (4d) |
| Jun 20, 2013 | ALIM | ↓ Sell | 114 | $5.01 | $571 | Direct | Jun 24, 2013 (4d) |
| Jun 19, 2013 | ALIM | ↓ Sell | 55,278 | $5.39 | $298K | Direct | Jun 20, 2013 (1d) |
| Jun 19, 2013 | ALIM | ↓ Sell | 603 | $5.39 | $3K | Direct | Jun 20, 2013 (1d) |
| Jun 17, 2013 | ALIM | ↓ Sell | 126,709 | $5.29 | $670K | Direct | Jun 18, 2013 (1d) |
| Jun 17, 2013 | ALIM | ↓ Sell | 1,384 | $5.29 | $7K | Direct | Jun 18, 2013 (1d) |
| Jun 11, 2013 | ALIM | ↓ Sell | 5,337 | $5.00 | $27K | Direct | Jun 13, 2013 (2d) |
| Jun 11, 2013 | ALIM | ↓ Sell | 59 | $5.00 | $295 | Direct | Jun 13, 2013 (2d) |
| Jun 4, 2013 | CLVS | ↓ Sell | 159,192 | $64.58 | $10.3M | Direct | Jun 5, 2013 (1d) |
| Jun 4, 2013 | CLVS | ↓ Sell | 2,779 | $64.58 | $179K | Direct | Jun 5, 2013 (1d) |
| May 16, 2013 | ALIM | ↓ Sell | 44,242 | $4.60 | $204K | Direct | May 17, 2013 (1d) |
| May 16, 2013 | ALIM | ↓ Sell | 483 | $4.60 | $2K | Direct | May 17, 2013 (1d) |
| Apr 15, 2013 | CADX | ↓ Sell | 71,578 | $6.62 | $474K | Direct | Apr 17, 2013 (2d) |
| Apr 15, 2013 | CADX | ↓ Sell | 23,210 | $6.62 | $154K | Direct | Apr 17, 2013 (2d) |
| Apr 10, 2013 | CADX | ↓ Sell | 77,622 | $6.62 | $514K | Direct | Apr 10, 2013 (0d) |
| Apr 10, 2013 | CADX | ↓ Sell | 25,170 | $6.62 | $167K | Direct | Apr 10, 2013 (0d) |
| Mar 21, 2013 | CADX | ↓ Sell | 13,490 | $5.35 | $72K | Direct | Mar 22, 2013 (1d) |
| Mar 21, 2013 | CADX | ↓ Sell | 4,374 | $5.35 | $23K | Direct | Mar 22, 2013 (1d) |
| Mar 21, 2013 | CADX | ↓ Sell | 1,743 | $5.49 | $10K | Direct | Mar 22, 2013 (1d) |
| Mar 21, 2013 | CADX | ↓ Sell | 893 | $5.49 | $5K | Direct | Mar 22, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 41,437 | $5.20 | $216K | Direct | Mar 21, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 13,435 | $5.20 | $70K | Direct | Mar 21, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 443 | $5.20 | $2K | Direct | Mar 21, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 226 | $5.20 | $1K | Direct | Mar 21, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 54,455 | $5.23 | $285K | Direct | Mar 19, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 17,656 | $5.23 | $92K | Direct | Mar 19, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 583 | $5.23 | $3K | Direct | Mar 19, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 298 | $5.23 | $2K | Direct | Mar 19, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 39,328 | $5.38 | $212K | Direct | Mar 15, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 12,753 | $5.38 | $69K | Direct | Mar 15, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 422 | $5.38 | $2K | Direct | Mar 15, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 216 | $5.38 | $1K | Direct | Mar 15, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kathleen K Schoemaker's insider trades
Kathleen K Schoemaker is a 10% owner of Evoke Pharma (EVOK). Since May 15, 2006, Kathleen has reported 51 open-market purchases worth $122.2M and 112 sales worth $64.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (40 filings), other transactions (24 filings), option exercises (9 filings), shares withheld for taxes (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EVOK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.